[Idiosyncratic drug-induced agranulocytosis: 7 year-analysis in a French university hospital].

Agranulocytoses médicamenteuses idiosyncrasiques : analyse de 7 ans dans un hôpital universitaire français.

Journal

Annales pharmaceutiques francaises
ISSN: 0003-4509
Titre abrégé: Ann Pharm Fr
Pays: France
ID NLM: 2985176R

Informations de publication

Date de publication:
May 2020
Historique:
received: 11 10 2019
revised: 31 01 2020
accepted: 03 02 2020
pubmed: 7 4 2020
medline: 6 3 2021
entrez: 7 4 2020
Statut: ppublish

Résumé

Idiosyncratic drug-induced agranulocytosis is a rare but potentially serious haematological disorder. The pathophysiological mechanisms are complex and poorly understood. We aimed at investigating agranulocytosis drug related causes from the myelograms with "myeloid maturation arrest" performed in our university hospital over the last seven years. A retrospective analysis of myelograms collected for agranulocytosis was performed from 1st January 2010 to 31th December 2016. We used the method of Bégaud et al. for drug causality assessment. Among the 104 myelograms analysed, 41 agranulocytosis were drug-induced, whose 28 were idiosyncratic. Among these 28 cases, 26 different drugs were involved. Agranulocytosis was a known adverse reaction in the summary of the product characteristics for 24 drugs, mainly associated with undetermined frequency (n=7). Mean onset latency was 38.1 days after starting the drug (calculated for n=23 cases) and granulocyte growth factors were used in 50% of cases without shortening the mean delay of blood count recovery. Bone marrow presented hypereosinophilia in 29% of cases. Pharmacovigilance reporting rate was 48%. A "maturation arrest" in the myelogram is not pathognomonic for idiosyncratic drug-induced agranulocytosis. This rare event require multidisciplinary care involving haematologists, biologists and pharmacovigilance experts. Agranulocytosis reporting rate was high compared with usual adverse drug reaction reporting rate (5 to 10%), probably related to the potential severity of this event.

Identifiants

pubmed: 32248952
pii: S0003-4509(20)30011-0
doi: 10.1016/j.pharma.2020.02.004
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

230-241

Informations de copyright

Copyright © 2020 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

M Duwez (M)

Département de pharmacie, CHU de Grenoble-Alpes, 38000 Grenoble, France. Electronic address: marion.duwez@hcuge.ch.

G Szymanski (G)

Laboratoire d'hématologie, CHU de Grenoble-Alpes, 38000 Grenoble, France.

M Carre (M)

Clinique universitaire d'hématologie, CHU de Grenoble-Alpes, 38000 Grenoble, France.

M Mallaret (M)

Centre régional de pharmacovigilance, CHU de Grenoble-Alpes, 38000 Grenoble, France.

M Lepelley (M)

Centre régional de pharmacovigilance, CHU de Grenoble-Alpes, 38000 Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH